PharmaCyte Share Price
NASDAQ: PMCB | Micro Cap | HealthcarePharmaCyte Stock Performance
PharmaCyte Share Price Chart
PharmaCyte Quarterly Profit & Loss
All figures in USD
PharmaCyte Annual Profit & Loss
All figures in USD
PharmaCyte Balance Sheet
All figures in USD Million
PharmaCyte Cash Flow
All figures in USD Million
Corporate Actions
About PharmaCyte
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
PharmaCyte Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Nov 2026 | $0.31 | $4.00 | +1,211.48% |
Oct 2026 | $0.40 | $0.30 | -30.21% |
Sep 2026 | $0.49 | $0.44 | -18.92% |
Aug 2026 | $0.57 | $0.54 | -5.44% |
Jul 2026 | $0.76 | $0.57 | -25.97% |
Jun 2026 | $0.81 | $0.77 | -5.87% |
May 2026 | $0.74 | $0.82 | +7.77% |
Apr 2026 | $0.71 | $0.76 | +15.00% |
Mar 2026 | $0.70 | $0.66 | -6.91% |
Feb 2026 | $0.80 | $0.71 | -12.68% |
Jan 2026 | $0.70 | $0.81 | +13.88% |
Dec 2025 | $0.75 | $0.71 | -7.40% |